RXi Pharmaceuticals Corp. (NASDAQ: RXII), a discovery-stage biopharmaceutical company, is focused on developing and commercializing proprietary therapeutics, based on RNA interference (RNAi), to treat various human diseases. The company aims to leverage RNAi-based technologies across multiple therapeutic areas to initially treat neurological diseases, metabolic diseases and cancer. For further information, visit the Company’s web site at www.rxipharma.com.
- 17 years ago
QualityStocks
RXi Pharmaceuticals Corp. (NASDAQ: RXII)
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer
The global rare disease treatment market was estimated at $195.2 billion in 2024 and is…
-
Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Is ‘One to Watch’
High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising…
-
QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Appoints Industry Veteran Jon Bond to Board of Directors
Onar (OTCQB: ONAR) announced the appointment of marketing pioneer Jon Bond to its board of…